en · de · es
aod-9604-notes.peptides4962.com › Data › Background And Research Context — What the Evidence Shows

Background And Research Context — What the Evidence Shows

By Editorial Desk · published 2025-12-22 · last reviewed 2026-01-25 · Data

If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Regulation and Detection Context

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Related pages on this site

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Identity and Research Origin

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Handling And Analytical Properties

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Further detail

Naturally occurring siRNAs have a well-defined structure that is a short (usually 20 to 24-bp) double-stranded RNA (dsRNA) with phosphorylated 5' ends and hydroxylated 3' ends with two overhanging nucleotides. As of 2001, it had been suggested that an enzyme referred to as Dicer catalyzed "the initiation step of RNA interference" (production of siRNAs from long dsRNAs and small hairpin RNAs). siRNAs can also be introduced into cells by transfection. Since, in principle, any gene can be knocked down by a synthetic siRNA with a complementary sequence, siRNAs are an important tool for validating gene function and drug targeting in the "post-genomic era".

is less than 10.5, the blocks will mix and microphase separation is not observed. The incompatibility between the blocks also affects the solution behavior of these copolymers and their adsorption behavior on various surfaces. Block copolymers are able to self-assemble in selective solvents to form micelles among other structures. In thin films, block copolymers are of great interest as masks in the lithographic patterning of semiconductor materials for applications in high density data storage. A key challenge is to minimise the feature size and much research is in progress on this.

=== Reactivation and transplantation === The specific triggers for reactivation are not well understood. Some researchers have suggested that injury, physical or emotional stress, and hormonal imbalances could be involved. Researchers during 2011 discovered that reactivation can positively be triggered in vitro by histone deacetylase inhibitors. Once reactivation begins, the rolling circle process is initiated and concatemers are formed as described above. A study published in The Journal of Infectious Diseases in 2024 investigated the reactivation of inherited chromosomally integrated human herpesvirus 6 (iciHHV-6B) in a liver transplant recipient and its impact on the graft. The research, conducted by Hannolainen et al., used hybrid capture sequencing and various molecular techniques to analyze the viral sequences and host immune response. The findings demonstrated active replication of iciHHV-6B and significant immune activation, suggesting the pathological impact of viral reactivation on transplant outcomes. The study emphasizes the importance of monitoring iciHHV-6 reactivation in transplant patients.

== Future research == The pathophysiology of IIMs is not well understood. Muscle weakness can be caused by a single or combined effect on muscle tissue by inflammation, inflammatory infiltrates, muscle atrophy, metabolic abnormalities that indicate disordered energy metabolism, and possibly neuropathy, among others. Therefore, physical exercise has the potential to cause harm. However, the results of these exercise studies, at minimum, show that exercise can attenuate muscle damage due to disease, inactivity and steroid use. They reflect the benefit of exercise through the strengthening of complement (non-diseased) muscles, and should encourage further studies to confirm whether diseased muscle may experience regeneration. The definition of improvement must be established, and reproducible longitudinal studies must be conducted to determine the efficacy of exercise as therapy for IIM.

==== Nations ==== India: Randhir Jaiswal, the official spokesperson of the Ministry of External Affairs, expressed strong condemnation of the strikes and expressed support for Afghanistan's sovereignty and territorial integrity. Qatar: Qatari foreign minister Mohammed bin Abdulaziz Al Khulaifi discussed with Pakistani Foreign Minister Muhammad Ishaq Dar ways to reduce tension between Pakistan and Afghanistan, thereby strengthening security and stability in the region. Russia: The Russian government offered to mediate the situation and urged both nations to halt cross-border attacks. Saudi Arabia: Prince Faisal bin Farhan and officials in the Pakistani government discussed ways to reduce regional tensions during a phone call. United States: The White House stated that it will continue to monitor the situation closely and expressed support for Pakistan against the Taliban attacks. US president Donald Trump praised both Shehbaz Sharif and Asim Munir for fighting against Taliban forces. In addition, Bangladesh, China, Egypt, Iran, Iraq, Jordan, Malaysia, and Uzbekistan also called for a ceasefire to end hostilities and promoted dialogue to resolve border tensions.

Sources: en.wikipedia.org

Background from the literature

The RSP is also connected to the shaft via the pars intermedia (venous plexus of Kobelt). When engorged with blood, the bulbs cuff the vaginal opening and cause the vulva to expand outward. Although several texts state that they surround the vaginal opening, Ginger et al. state that this does not appear to be the case and tunica albuginea does not envelop the erectile tissue of the bulbs. In Yang et al.'s assessment of the bulbs' anatomy, they conclude that the bulbs "arch over the distal urethra, outlining what might be appropriately called the 'bulbar urethra' in women".

An isobaric tag for relative and absolute quantitation (iTRAQ) is a reagent for tandem mass spectrometry that is used to determine the amount of proteins from different sources in a single experiment. It uses stable isotope labeled molecules that can form a covalent bond with the N-terminus and side chain amines of proteins. The iTRAQ reagents are used to label peptides from different samples that are pooled and analyzed by liquid chromatography and tandem mass spectrometry. The fragmentation of the attached tag generates a low molecular mass reporter ion that can be used to relatively quantify the peptides and the proteins from which they originated.

In situ conservation Ex situ conservation List of colossal sculptures in situ List of Latin phrases Neoclassical compound – Compound words composed from Latin or ancient Greek All pages with titles beginning with In situ

==== Full-size DisplayPort connector ==== The standard DisplayPort connector (now referred to as a "full-size" connector to distinguish it from the mini connector) was the sole connector type introduced in DisplayPort 1.0. It is a 20-pin single-orientation connector with a friction lock and an optional mechanical latch. The standard DisplayPort receptacle has dimensions of 16.10 mm (width) × 4.76 mm (height) × 8.88 mm (depth). The standard DisplayPort connector pin allocation is as follows:

== Mechanism == Subunit vaccines contain fragments of the pathogen, such as protein or polysaccharide, whose combinations are carefully selected to induce a strong and effective immune response. Because the immune system interacts with the pathogen in a limited way, the risk of side effects is minimal. An effective vaccine would elicit the immune response to the antigens and form immunological memory that allows quick recognition of the pathogens and quick response to future infections. A drawback is that the specific antigens used in a subunit vaccine may lack pathogen-associated molecular patterns which are common to a class of pathogen. These molecular structures may be used by immune cells for danger recognition, so without them, the immune response may be weaker. Another drawback is that the antigens do not infect cells, so the immune response to the subunit vaccines may only be antibody-mediated, not cell-mediated, and as a result, is weaker than those elicited by other types of vaccines. To increase immune response, adjuvants may be used with the subunit vaccines, or booster doses may be required.

Sources: en.wikipedia.org

Reference notes

=== Procedures === More advanced cases may be resistant or unresponsive to medical therapy and require hair transplantation. Naturally occurring units of one to four hairs, called follicular units, are excised and moved to areas of hair restoration. These follicular units are surgically implanted in the scalp in proximity and in large numbers. The grafts are obtained from either follicular unit transplantation (FUT) or follicular unit extraction (FUE). In the former, a strip of skin with follicular units is extracted and dissected into individual follicular unit grafts, and in the latter, individual hairs are extracted manually or robotically. The surgeon then implants the grafts into small incisions, called recipient sites. Cosmetic scalp tattoos can also mimic the appearance of a short, buzzed haircut.

The possibility of a militarized Japan has also been a continuous concern to the Chinese leadership since the late 1990s. In addition, China's military leadership has been reacting to and learning from the successes and failures of the United States Armed Forces during the Kosovo War, the 2001 invasion of Afghanistan, the 2003 invasion of Iraq, and the Iraqi insurgency. All these lessons inspired China to transform the PLA from a military based on quantity to one based on quality. Chairman Jiang Zemin officially made a "revolution in military affairs" (RMA) part of the official national military strategy in 1993 to modernize the Chinese armed forces. A goal of the RMA is to transform the PLA into a force capable of winning what it calls "local wars under high-tech conditions" rather than a massive, numbers-dominated ground-type war. Chinese military planners call for short decisive campaigns, limited in both their geographic scope and their political goals. In contrast to the past, more attention is given to reconnaissance, mobility, and deep reach. This new vision has shifted resources towards the navy and air force. The PLA is also actively preparing for space warfare and cyber-warfare. In 2002, the PLA began holding military exercises with militaries from other countries. From 2018 to 2023, more than half of these exercises have focused on military training other than war, generally antipiracy, or antiterrorism exercises involving combatting non-state actors.

== Habitat == Hydras are often found in freshwater bodies, but some Hydras are found in open water. They live attached to submerged rocks using a sticky secretion from their base. The genus Hydra occurs on all continents except for Antarctica and the Oceanic islands, though Hydras occur mainly in mesotrophic to eutrophic habitats.

=== Atomic and molecular physics === Some atomic energy levels are metastable. Rydberg atoms are an example of metastable excited atomic states. Transitions from metastable excited levels are typically those forbidden by electric dipole selection rules. This means that any transitions from this level are relatively unlikely to occur. In a sense, an electron that happens to find itself in a metastable configuration is trapped there. Since transitions from a metastable state are not impossible (merely less likely), the electron will eventually decay to a less energetic state, typically by an electric quadrupole transition, or often by non-radiative de-excitation (e.g., collisional de-excitation). This slow-decay property of a metastable state is apparent in phosphorescence, the kind of photoluminescence seen in glow-in-the-dark toys that can be charged by first being exposed to bright light. Whereas spontaneous emission in atoms has a typical timescale on the order of 10−8 seconds, the decay of metastable states can typically take milliseconds to minutes, and so light emitted in phosphorescence is usually both weak and long-lasting.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

Is AOD-9604 banned in sport?

Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.

Network